Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Alexander C. J. van Akkooi, Michal Kiciński et al.|The Lancet Oncology|2025Cited by 10
961 Preliminary results of a phase 2 study of intratumoral administration of BO-112 with pembrolizumab in patients with advanced melanoma that have progressive disease on anti-PD-1-based therapyIván Márquez‐Rodas, Stéphane Dalle, Philippe Saïag et al.|Unknown|2021Cited by 8
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with ImmunotherapyElena Garralda, Rodrigo A. Toledo, Vladimir Galvao et al.|Clinical Cancer Research|2025Cited by 1